Pathogenesis of nonalcoholic steatohepatitis (NASH)

Chinese Journal of Digestive Diseases

Volumn 7, Issue 1, 2006, Pages 7-11

  Ma, Xiong ^a,b   Li, Zhiping ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytokines; Natural killer T cells; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Obesity

Indexed keywords

CYTOKINE; FATTY ACID; INSULIN; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

CYTOKINE PRODUCTION; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPIDEMIOLOGICAL DATA; FATTY LIVER; HUMAN; IMMUNITY; IMMUNOREGULATION; INSULIN RESISTANCE; INTESTINE FLORA; LIVER CELL; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT; REVIEW; T LYMPHOCYTE;

CLINICAL TRIALS; CYTOKINES; FATTY LIVER; HUMANS; OXIDATION-REDUCTION;

EID: 33644897340     PISSN: 14439611     EISSN: 14439573     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2006.00237.x     Document Type: Review

References (50)

1. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
4. Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-14.
5. Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: An epidemiological survey. World J Gastroenterol 2003; 9: 1106-10.
6. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999; 116: 1413-19.
7. Teli M, James OF, Burt AD, Bennett MK, Day CP. A natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714-17.
8. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-8.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
10. Bacon B, Faravash MJ, Janney CG et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107: 1103-6.
11. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histopathological comparison with alcohol-induced liver injury. Gastroenterology 1989; 95: 1056-60.
12. Powell EE, Cooksley GE, Hanson R, Searle J, Halliday RW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990; 11: 74-80.
13. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
14. Gines P, Quintero E, Arroyo V et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology 1987; 7: 122-8.
15. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
16. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
17. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
18. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
19. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
20. Marchesini G, Brizl M, Bianchi G, Tomasselli S, Zoll M, Melchlonda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
21. Caldwell SH, Hespenheide EE, Redick JA et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastro 2001; 96: 519-25.
22. Day CP, James O. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
23. Bass NM, Raghupathy E, Rhoads DE, Manning JA, Ockner RK. Partial purification of molecular weight 12 0 00 fatty acid binding proteins from rat brain and their effect on synaptosomal Na+-dependent amino acid uptake. Biochemistry 1984; 23: 6539-44.
24. Schonfeld P, Wieckowski MR, Wojtczak L. Long-chain fatty acid-promoted swelling of mitochondria: Further evidence for the protonophoric effect of fatty acids in the inner mitochondrial membrane. FEBS Lett 2000; 471: 108-12.
25. Nguyen N, Glanz D, Glaesser D. Fatty acid cytotoxicity to bovine lens epithelial cells: Investigations on cell viability, ecto-ATPase, Na(+), K(+)-ATPase and intracellular sodium concentrations. Exp Eye Res 2000; 71: 405-13.
26. Ockner RK. Apoptosis and liver diseases: Recent concepts of mechanism and significance. J Gastroenterol Hepatol 2001; 16: 248-60.
27. Wu D, Cederbaum AI. Cyclosporine A protects against arachidonic acid toxicity in rat hepatocytes: Role of CYP2E1 and mitochondria. Hepatology 2002; 35: 1420-30.
28. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
29. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
30. Vendemiale G, Grattagliano I, Caraceni P et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. Hepatology 2001; 33: 808-15.
31. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. JAMA 1999; 282: 1659-64.
32. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
33. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
34. Godfrey DI, Hammond KL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-83.
35. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science 2002; 296: 553-5.
36. Shiratori Y, Kawase T, Komatsu Y et al. Endotoxin induced cellular communication in the liver: Murine models for clarification of the role of LPS-responsive macrophages in the pathogenesis of liver diseases. J Gastroenterol Hepatol 1995; 10: S97-100.
37. Frey AB, Rao TD. NKT cell cytokine imbalance in murine diabetes mellitus. Autoimmunity 1999; 29: 201-14.
38. Wilson MT, Van Kaer L. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des 2003; 9: 201-20.
39. Li Z, Lin HZ, Yang SQ, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002; 123: 1304-10.
40. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42: 880-5.
41. Li Z, Oben JA, Yang S et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004; 40: 434-41.
42. Kern PA, Saghizaheh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-9.
43. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
44. Loguercio C, DeSimone T, Federico A et al. Gut-liver axis: A new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144-6.
45. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
46. Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46.
47. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK beta. Science 2001; 293: 1673-7.
48. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NK-kappa B. Ann Rheum Dis 2000; 59: I6-16.
49. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin-resistance in mice lacking TNF alpha function. Nature 1997; 389: 610-14.
50. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.